Cases & Deals

  • Home
  • Practices
  • Celgene prevails in district court case, beating back patent infringement claims directed against its Abraxane® brand cancer drug

Share

Celgene prevails in district court case, beating back patent infringement claims directed against its Abraxane® brand cancer drug

March 2014

Client(s) Celgene Corporation

Jones Day successfully defended Celgene Corporation and its subsidiary Abraxis BioScience, LLC in a patent infringement case brought in the United States District Court for the District of Massachusetts by Cephalon, Inc. and Acusphere, Inc. alleging Celgene's ABRAXANE® brand cancer drug infringed U.S. Patent No. RE40,493 ("the '493 patent'). After Jones Day obtained a favorable claim construction ruling, the plaintiffs agreed that ABRAXANE® did not infringe any valid claim of the '493 patent and stipulated to the entry of a final judgment of noninfringement.

Cephalon, Inc. et al. v. Celgene Corp. et al., Civil Action No. 1-11-cv-12226 (D. Mass.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.